NMDA receptor in the hippocampus alters neurobehavioral phenotypes through inflammatory cytokines in rats with sporadic Alzheimer-like disease

Many patients with sporadic Alzheimer's disease (AD) suffer from memory impairment, anxiety- and depression. The systemic utility of N-Methyl-d-Aspartate (NMDA) receptor antagonists has been shown to be potential therapeutic target for memory loss in AD. However, there is no evidence that shows...

Full description

Saved in:
Bibliographic Details
Published in:Physiology & behavior 2019-04, Vol.202, p.52-61
Main Authors: Amani, Mohammad, Zolghadrnasab, Maryam, Salari, Ali-Akbar
Format: Article
Language:English
Subjects:
Alzheimer Disease - metabolism
Animals
Anxiety
Anxiety - metabolism
Cytokines - metabolism
Depression
Depression - metabolism
Disease Models, Animal
Dizocilpine Maleate - pharmacology
Excitotoxicity
Glutamate
Hippocampus - metabolism
Interleukin-1beta - metabolism
Interleukin-6 - metabolism
Male
Maze Learning
Memory
MK-801
Phenotype
Rats
Rats, Wistar
Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors
Receptors, N-Methyl-D-Aspartate - metabolism
Tumor Necrosis Factor-alpha - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many patients with sporadic Alzheimer's disease (AD) suffer from memory impairment, anxiety- and depression. The systemic utility of N-Methyl-d-Aspartate (NMDA) receptor antagonists has been shown to be potential therapeutic target for memory loss in AD. However, there is no evidence that shows whether NMDA receptor antagonists have the same effects when these blockers are directly used within the brain regions including hippocampus. It might be an urgent to further explore the therapeutic role of NMDA receptor antagonists in behavioral abnormalities such as anxiety and depression in AD. The aim of this study was to determine whether blockade of the hippocampal NMDA receptors could attenuate neurobehavioral abnormalities in rats with sporadic AD. Twelve days after AD induction by streptozotocin (STZ), animals received either vehicle or MK-801 (NMDA receptor antagonist) in the hippocampus for 10 days. Two or five days after the last MK-801 treatment, spatial memory, anxiety- and depression-related behaviors, and inflammatory cytokines (interleukin-(IL)-6, IL-1β and tumor necrosis factor (TNF)-α) were evaluated. Our findings indicated that STZ treatment significantly elevated hippocampal inflammation, impaired spatial memory, and increased anxiety- and depression-related symptoms in rats. Interestingly, the hippocampal NMDA receptor blockade improved these neurobehavioral phenotypes and decreased inflammatory cytokines in the hippocampus of STZ-treated rats. Hippocampal NMDA receptors might be involved in neurobehavioral abnormalities via inflammation in sporadic AD. •Sporadic Alzheimer-like disease was induced by ICV injection of streptozocin (STZ).•Hippocampal NMDA receptor blockade improved memory in STZ-treated rats.•Hippocampal NMDA receptor blockade decreased anxiety behavior in STZ-treated rats.•Hippocampal NMDA receptor blockade reduced depression symptoms in STZ-treated rats.•NMDA receptor blockade reduced hippocampal inflammation in STZ-treated rats.
ISSN:0031-9384
1873-507X
DOI:10.1016/j.physbeh.2019.01.005